Cerus (CERS) Q4 2024 earnings summary

Executive summary

• Achieved 15% year-over-year product revenue growth in 2024, reaching $180.3 million, with strong momentum in platelet and IFC franchises and global expansion.

• Posted positive adjusted EBITDA of $5.7 million for 2024, marking the first full year of profitability on this metric, and improved GAAP net loss by over 40% to $20.9 million.

• Achieved four consecutive quarters of positive operating cash flow, totaling $11.4 million for 2024.

• Exited 2024 with strong momentum in both platelet and IFC franchises, positioning for continued growth in 2025.

• 2025 guidance anticipates 8–11% product revenue growth, driven by U.S. platelet share, global expansion, and increased IFC manufacturing capacity.

Financial highlights

• Full year 2024 product revenues reached $180.3 million, up 15% year-over-year and ahead of guidance; Q4 2024 product revenue was $50.8 million, up 9% year-over-year.

• IFC business grew 42% in 2024 to $9.2 million; Q4 2024 IFC sales rose nearly 30% year-over-year.

• Product gross profit for 2024 was $99.5 million, with gross margins at 55.2%.

• Reported net loss for 2024 improved by 44% to $20.9 million; Q4 net loss was $2.5 million.

• Ended Q4 2024 with $80.5 million in cash, cash equivalents, and short-term investments.

Outlook and guidance

• 2025 product revenue guidance projects 8–11% year-over-year growth, or $194–$200 million, with IFC revenue guided to $12–$15 million.

• Expect continued positive adjusted EBITDA and operating cash flows in 2025, with further improvement in GAAP net loss.

• Anticipate gross margins to remain in the mid-50% range, with some quarterly variability possible.

• SG&A expenses expected to rise modestly in 2025 due to inflation, but no significant new investments planned.

• Growth drivers include U.S. platelet share, global expansion, increased IFC capacity, and LED Illuminator launch in EMEA.